Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All deuremidevir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchDeuremidevirDeuremidevir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Remdesivir Derivative VV116 Is a Potential Broad-Spectrum Inhibitor of Both Human and Animal Coronaviruses

Liu et al., Viruses, doi:10.3390/v15122295
Nov 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
In Vitro study showing the remdesivir derivative VV116 exhibits broad-spectrum inhibition against human coronaviruses (HCoV-NL63, HCoV-229E, HCoV-OC43) and animal coronaviruses (MHV, FIPV, FECV, CCoV) without cytotoxicity. Through time-of-addition and competitive inhibition assays, authors find VV116 likely inhibits viral RNA-dependent RNA polymerase activity during genome replication. An MHV mouse model further confirms VV116's efficacy in vivo, alleviating symptoms and protecting against infection-induced mortality.
2 preclinical studies support the efficacy of deuremidevir for COVID-19:
Liu et al., 23 Nov 2023, peer-reviewed, 7 authors. Contact: mvlwu@whu.edu.cn (corresponding author), wyliu@hust.edu.cn, huchengxiuamma@163.com, shj18134682591@163.com, zhangmin_701@163.com, 15972986161@163.com, gracetey@whu.edu.cn.
This PaperDeuremidevirAll
Remdesivir Derivative VV116 Is a Potential Broad-Spectrum Inhibitor of Both Human and Animal Coronaviruses
Weiyong Liu, Min Zhang, Chengxiu Hu, Huijuan Song, Yi Mei, Yingle Liu, Qi Zhang
Viruses, doi:10.3390/v15122295
Coronaviruses represent a significant threat to both human and animal health, encompassing a range of pathogenic strains responsible for illnesses, from the common cold to more severe diseases. VV116 is a deuterated derivative of Remdesivir with oral bioavailability that was found to potently inhibit SARS-CoV-2. In this work, we investigated the broad-spectrum antiviral activity of VV116 against a variety of human and animal coronaviruses. We examined the inhibitory effects of VV116 on the replication of the human coronaviruses HCoV-NL63, HCoV-229E, and HCoV-OC43, as well as the animal coronaviruses MHV, FIPV, FECV, and CCoV. The findings reveal that VV116 effectively inhibits viral replication across these strains without exhibiting cytotoxicity, indicating its potential for safe therapeutic use. Based on the results of a time-of-addition assay and an rNTP competitive inhibition assay, it is speculated that the inhibitory mechanism of VV116 against HCoV-NL63 is consistent with its inhibition of SARS-CoV-2. Our work presents VV116 as a promising candidate for broad-spectrum anti-coronavirus therapy, with implications for both human and animal health, and supports the expansion of its therapeutic applications as backed by detailed experimental data.
Conflicts of Interest: The authors declare no conflict of interest.
References
Agostini, Andres, Sims, Graham, Sheahan et al., Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease, mBio, doi:10.1128/mBio.00221-18
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of COVID-19-Final Report, N. Engl. J. Med, doi:10.1056/NEJMoa2007764
Binn, Lazar, Keenan, Huxsoll, Marchwicki et al., Recovery and Characterization of a Coronavirus from Military Dogs with Diarrhea
Bravo, Dangerfield, Taylor, Johnson, Remdesivir Is a Delayed Translocation Inhibitor of SARS-CoV-2 Replication, Mol. Cell, doi:10.1016/j.molcel.2021.01.035
Cao, Gao, Bao, Feng, Mei et al., VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2208822
Chan-Yeung, Xu, Sars, None, Epidemiology, doi:10.1046/j.1440-1843.2003.00518.x
Corman, Eckerle, Memish, Liljander, Dijkman et al., Link of a Ubiquitous Human Coronavirus to Dromedary Camels, Proc. Natl. Acad. Sci, doi:10.1073/pnas.1604472113
Ebihara, Endo, Ma, Ishiguro, Kikuta, Detection of Human Coronavirus NL63 in Young Children with Bronchiolitis, J. Med. Virol, doi:10.1002/jmv.20289
Gaye, Fanidi, Jouven, Denominator Matters in Estimating COVID-19 Mortality Rates, Eur. Heart J, doi:10.1093/eurheartj/ehaa282
Grabherr, Ludewig, Pikor, Insights into Coronavirus Immunity Taught by the Murine Coronavirus, Eur. J. Immunol, doi:10.1002/eji.202048984
Khan, El Morabet, Khan, Bindajam, Alqadhi et al., Where We Missed? Middle East Respiratory Syndrome (MERS-CoV) Epidemiology in Saudi Arabia; 2012-2019, Sci. Total Environ, doi:10.1016/j.scitotenv.2020.141369
Liu, Liang, Fung, Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae), doi:10.1016/B978-0-12-809633-8.21501-X
Mccarthy, VV116 as a Potential Treatment for COVID-19, Expert Opin. Pharmacother, doi:10.1080/14656566.2023.2193668
Mesel-Lemoine, Millet, Vidalain, Law, Vabret et al., A Human Coronavirus Responsible for the Common Cold Massively Kills Dendritic Cells but Not Monocytes, J. Virol, doi:10.1128/JVI.00269-12
Milewska, Zarebski, Nowak, Stozek, Potempa et al., Human Coronavirus NL63 Utilizes Heparan Sulfate Proteoglycans for Attachment to Target Cells, J. Virol, doi:10.1128/JVI.02078-14
Nova, Cross-Species Transmission of Coronaviruses in Humans and Domestic Mammals, What Are the Ecological Mechanisms Driving Transmission, Spillover, and Disease Emergence? Front, Public Health, doi:10.3389/fpubh.2021.717941
Ogando, Dalebout, Zevenhoven-Dobbe, Limpens, Van Der Meer et al., SARS-Coronavirus-2 Replication in Vero E6 Cells: Replication Kinetics, Rapid Adaptation and Cytopathology, J. Gen. Virol, doi:10.1099/jgv.0.001453
Pene, Merlat, Vabret, Rozenberg, Buzyn et al., Coronavirus 229E-Related Pneumonia in Immunocompromised Patients, Clin. Infect. Dis, doi:10.1086/377612
Pizzorno, Padey, Dubois, Julien, Traversier et al., In Vitro Evaluation of Antiviral Activity of Single and Combined Repurposable Drugs against SARS-CoV-2, Antivir. Res, doi:10.1016/j.antiviral.2020.104878
Qian, Wang, Zhang, Xie, Wu et al., Tolerability, and Pharmacokinetics of VV116, an Oral Nucleoside Analog against SARS-CoV-2, in Chinese Healthy Subjects, Acta Pharmacol. Sin, doi:10.1038/s41401-022-00895-6
Rottier, Nakamura, Schellen, Volders, Haijema, Acquisition of Macrophage Tropism during the Pathogenesis of Feline Infectious Peritonitis Is Determined by Mutations in the Feline Coronavirus Spike Protein, J. Virol, doi:10.1128/JVI.79.22.14122-14130.2005
Seley-Radtke, Yates, The Evolution of Nucleoside Analogue Antivirals: A Review for Chemists and Non-Chemists. Part 1: Early Structural Modifications to the Nucleoside Scaffold, Antivir. Res, doi:10.1016/j.antiviral.2018.04.004
Sheahan, Sims, Graham, Menachery, Gralinski et al., Broad-Spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses, Sci. Transl. Med, doi:10.1126/scitranslmed.aal3653
Sheahan, Sims, Leist, Schäfer, Won et al., Comparative Therapeutic Efficacy of Remdesivir and Combination Lopinavir, Ritonavir, and Interferon Beta against MERS-CoV, Nat. Commun, doi:10.1038/s41467-019-13940-6
Shen, Ai, Lin, Zhang, Li et al., An Open, Prospective Cohort Study of VV116 in Chinese Participants Infected with SARS-CoV-2 Omicron Variants, Emerg. Microbes Infect, doi:10.1080/22221751.2022.2078230
Silva, Mullis, Pereira, Saif, Vlasova et al., Human Respiratory Coronaviruses Detected In Patients with Influenza-Like Illness in Arkansas, USA, Virol. Mycol, doi:10.4172/2161-0517.S2-004
Tennant, Gaskell, Kelly, Carter, Gaskell, Canine Coronavirus Infection in the Dog Following Oronasal Inoculation, Res. Vet. Sci, doi:10.1016/0034-5288(91)90023-H
Tyrrell, Bynoe, Cultivation of a Novel Type of Common-Cold Virus in Organ Cultures, Br. Med. J, doi:10.1136/bmj.1.5448.1467
Vijgen, Keyaerts, Moës, Thoelen, Wollants et al., Complete Genomic Sequence of Human Coronavirus OC43: Molecular Clock Analysis Suggests a Relatively Recent Zoonotic Coronavirus Transmission Event, J. Virol, doi:10.1128/JVI.79.3.1595-1604.2005
Vlasova, Diaz, Damtie, Xiu, Toh et al., Novel Canine Coronavirus Isolated from a Hospitalized Patient With Pneumonia in East Malaysia, Clin. Infect. Dis
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Ward, Morphogenesis of a Virus in Cats with Experimental Feline Infectious Peritonitis, Virology, doi:10.1016/0042-6822(70)90070-X
Warren, Jordan, Lo, Ray, Mackman et al., Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola Virus in Rhesus Monkeys, Nature, doi:10.1038/nature17180
Xie, Yin, Zhang, Shang, Wang et al., Design and Development of an Oral Remdesivir Derivative VV116 against SARS-CoV-2, Cell Res, doi:10.1038/s41422-021-00570-1
Yates, Seley-Radtke, The Evolution of Antiviral Nucleoside Analogues: A Review for Chemists and Non-Chemists. Part II: Complex Modifications to the Nucleoside Scaffold, Antivir. Res, doi:10.1016/j.antiviral.2018.11.016
Zhang, Zhang, Zheng, Shang, Wu et al., Oral Remdesivir Derivative VV116 Is a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in Mouse Model, Signal Transduct. Target. Ther, doi:10.1038/s41392-022-00963-7
Zhu, Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19, ACS Pharmacol. Transl. Sci, doi:10.1021/acsptsci.3c00134
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit